LY-301317
pharmaceutical compound
LY-301317, also known as (R)-4,α-methylene-5-(1,3-oxazol-5-yl)-N,N-dipropyltryptamine ((R)-4,α-methylene-5-(1,3-oxazol-5-yl)-DPT), is a potent and selective serotonin 5-HT1A receptor agonist which has been used in scientific research. It is a cyclized tryptamine and a partial ergoline. The drug shows very high affinity for the serotonin 5-HT1A receptor, with a Ki of 0.26 nM, and is highly selective for this receptor over 9 other assessed targets. It produces various serotonin 5-HT1A receptor agonist-associated effects in animals, including behavioral effects, hypothermia, antidepressant-like, anxiolytic-like, and antiemetic effects, and discriminative stimulus effects in drug discrimination tests. LY-301317 was first described in the scientific literature in 1996.
Begin with the source’s own compact description: “LY-301317” is pharmaceutical compound. The dossier treats that line as a proposition to test through LY-301317, pharmaceutical and compound, not as a finished interpretation.
Why this record matters
The phrase “pharmaceutical compound” supplies a clear boundary for inquiry. It also exposes the unanswered questions: who defined that boundary, when it became stable and which sources sit outside it.
The citation trail is more important than the brevity of the summary: it shows where individual claims can be examined in context. The source revision retrieved here is dated Jun 8, 2026. The linked authority identifier is Q140137828. None of the 0 selected statements returned an explicit reference. The first chronological checks are 1996.
Overview language is designed for orientation and should not be treated as a substitute for the evidence cited beneath it. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “LY-301317”, its source revision and the description used here.
- Expand the search: follow LY-301317 primary sources, LY-301317 archive and LY-301317 research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “LY-301317”?
- Which cited source is closest to the event, object or claim?
- What terminology or title could unlock a more precise catalogue search?
Search terms from this dossier
This entry incorporates text from “LY-301317” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.